Frontage Holdings Corporation (1521.HK) HKSE

1.10

-0.05(-4.35%)

Updated at October 17 04:08PM

Currency In HKD

Frontage Holdings Corporation

Address

700 Pennsylvania Drive

Exton, PA 19341

United States of America

Phone

610 232 0100

Sector

Healthcare

Industry

Biotechnology

Employees

1560

First IPO Date

May 30, 2019

Key Executives

NameTitlePayYear Born
Dr. Wentao Zhang Ph.D.Co-Chief Executive Officer01969
Dr. Zhongping Lin Ph.D.Co-Chief Executive Officer01964
Mr. Jun GaoChief Financial Officer & President of Asia Pacific70,3951976
Dr. Song Li Ph.D.Founder & Chairman4.94M1957
Dr. Abdul Ezaz Mutlib Ph.D.Chief Scientific & Strategy Officer5.4M1961
Mr. Sudendra Rao Ph.D.Senior Vice President of Human Resources - North America0N/A
Mr. Richard Fischetti J.D.Vice President & General Counsel of Frontage Labs01983
Dr. Tianyi ZhangSenior Vice President of the Group & GM of Frontage Shanghai01969
Dr. Dongmei Wang Ph.D.Executive Vice President of Global Sales & Marketing and Project Management01965
Dr. John Kapeghian Ph.D.Executive Vice President of Global Safety & Toxicology0N/A

Description

Frontage Holdings Corporation, a contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies, as well as bioequivalence studies. It offers laboratory testing services, such as method development and validation, and sample analysis and central laboratory services; chemistry, manufacturing, and control services, including assistance in drug product development and analysis, and delivery and supply of clinical trial materials; and drug metabolism and pharmacokinetic services that include study designs, execution of studies, and interpretation of the data through structural optimization in early discovery, pharmacokinetic studies in rodents, non- GLP bioanalytical studies, etc. The company also provides safety and toxicology services comprising in-vitro and in-vivo studies; bioequivalence services, which consist of designing, coordinating, and reporting of bioequivalence studies; chemistry services comprising contract research and custom synthesis services; and clinical services, such as early stage clinical, BE/BA, biometric, and data management services. It operates in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. The company was incorporated in 2018 and is headquartered in Exton, Pennsylvania. Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.